Literature DB >> 10521302

Transfection of BLM into cultured bloom syndrome cells reduces the sister-chromatid exchange rate toward normal.

N A Ellis1, M Proytcheva, M M Sanz, T Z Ye, J German.   

Abstract

The gene BLM, mutated in Bloom syndrome (BS), encodes the nuclear protein BLM, which when absent, as it is from most BS cells, results in genomic instability. A manifestation of this instability is an excessive rate of sister-chromatid exchange (SCE). Here we describe the effects on this abnormal cellular phenotype of stable transfection of normal BLM cDNAs into two types of BS cells, SV40-transformed fibroblasts and Epstein-Barr virus (EBV)-transformed lymphoblastoid cells. Clones of BLM-transfected fibroblasts produced normal amounts of BLM by western blot analysis and displayed a normal nuclear localization of the protein by immunofluorescence microscopy. They had a mean of 24 SCEs/46 chromosomes, in contrast to the mean of 69 SCEs in controls transfected only with the vector. BLM-transfected fibroblast clones that expressed highest levels of the BLM protein had lowest levels of SCE. The lymphoblastoid cells transfected with BLM had SCE frequencies of 22 and 42 in two separate experiments in which two different selectable markers were used, in contrast to 57 and 58 in vector-transfected cells; in this type cell, however, the BLM protein was below the level detectable by western blot analysis. These experiments prove that BLM cDNA encodes a functional protein capable of restoring to or toward normal the uniquely characteristic high-SCE phenotype of BS cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521302      PMCID: PMC1288289          DOI: 10.1086/302616

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Elevated sister chromatid exchange phenotype of Bloom syndrome cells is complemented by human chromosome 15.

Authors:  L D McDaniel; R A Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Cloning of cDNAs for Fanconi's anaemia by functional complementation.

Authors:  C A Strathdee; H Gavish; W R Shannon; M Buchwald
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

3.  Correction of the Bloom syndrome cellular phenotypes.

Authors:  T Giesler; K Baker; B Zhang; L D McDaniel; R A Schultz
Journal:  Somat Cell Mol Genet       Date:  1997-09

4.  Bloom's syndrome. IV. Sister-chromatid exchanges in lymphocytes.

Authors:  J German; S Schonberg; E Louie; R S Chaganti
Journal:  Am J Hum Genet       Date:  1977-05       Impact factor: 11.025

5.  The Bloom's syndrome gene product is homologous to RecQ helicases.

Authors:  N A Ellis; J Groden; T Z Ye; J Straughen; D J Lennon; S Ciocci; M Proytcheva; J German
Journal:  Cell       Date:  1995-11-17       Impact factor: 41.582

6.  The DNA helicase activity of BLM is necessary for the correction of the genomic instability of bloom syndrome cells.

Authors:  N F Neff; N A Ellis; T Z Ye; J Noonan; K Huang; M Sanz; M Proytcheva
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

7.  Bloom syndrome: a mendelian prototype of somatic mutational disease.

Authors:  J German
Journal:  Medicine (Baltimore)       Date:  1993-11       Impact factor: 1.889

  7 in total
  13 in total

1.  The HRDC domain of BLM is required for the dissolution of double Holliday junctions.

Authors:  Leonard Wu; Kok Lung Chan; Christine Ralf; Douglas A Bernstein; Patrick L Garcia; Vilhelm A Bohr; Alessandro Vindigni; Pavel Janscak; James L Keck; Ian D Hickson
Journal:  EMBO J       Date:  2005-06-30       Impact factor: 11.598

2.  A novel frameshift mutation in BLM gene associated with high sister chromatid exchanges (SCE) in heterozygous family members.

Authors:  Ghada Ben Salah; Ikhlas Hadj Salem; Abderrahmen Masmoudi; Fakhri Kallabi; Hamida Turki; Faiza Fakhfakh; Hamadi Ayadi; Hassen Kamoun
Journal:  Mol Biol Rep       Date:  2014-08-17       Impact factor: 2.316

3.  Mechanisms of recombination between diverged sequences in wild-type and BLM-deficient mouse and human cells.

Authors:  Jeannine R Larocque; Maria Jasin
Journal:  Mol Cell Biol       Date:  2010-02-12       Impact factor: 4.272

4.  Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy.

Authors:  Vibhor Gupta; Ponnusamy Kalaiarasan; Mohammad Faheem; Nishant Singh; Mohammad Askandar Iqbal; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

Review 5.  Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition.

Authors:  Christopher Cunniff; Jennifer A Bassetti; Nathan A Ellis
Journal:  Mol Syndromol       Date:  2016-11-05

Review 6.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

7.  Aberrant chromosome morphology in human cells defective for Holliday junction resolution.

Authors:  Thomas Wechsler; Scott Newman; Stephen C West
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

8.  Identification of RecQL1 as a Holliday junction processing enzyme in human cell lines.

Authors:  Gary LeRoy; Robert Carroll; Saw Kyin; Masayuki Seki; Michael D Cole
Journal:  Nucleic Acids Res       Date:  2005-10-31       Impact factor: 16.971

9.  SUMO modification regulates BLM and RAD51 interaction at damaged replication forks.

Authors:  Karen J Ouyang; Leslie L Woo; Jianmei Zhu; Dezheng Huo; Michael J Matunis; Nathan A Ellis
Journal:  PLoS Biol       Date:  2009-12-01       Impact factor: 8.029

10.  Distinct pathways of homologous recombination controlled by the SWS1-SWSAP1-SPIDR complex.

Authors:  Rohit Prakash; Thomas Sandoval; Florian Morati; Jennifer A Zagelbaum; Pei-Xin Lim; Travis White; Brett Taylor; Raymond Wang; Emilie C B Desclos; Meghan R Sullivan; Hayley L Rein; Kara A Bernstein; Przemek M Krawczyk; Jean Gautier; Mauro Modesti; Fabio Vanoli; Maria Jasin
Journal:  Nat Commun       Date:  2021-07-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.